82 results about "Lenvatinib" patented technology

The invention provides a eutectic complex composed of resveratrol and a protein kinase inhibitor, and a composition comprising the eutectic complex. The eutectic complex is characterized in that the protein kinase inhibitor is selected from one of imatinib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib, lapatinib, nilotinib, pazopanib, afatinib, crizotinib, axitinib, regorafenib, ibrutinib, lenvatinib, palbociclib, osimertinib and alectinib or pharmaceutically acceptable salt thereof. The eutectic complex provided by the invention can produce synergistic effects of inhibiting histamine release.

The invention relates to a preparation method of lenvatinib, in particular to the preparation of lenvatinib through a one-step urea forming reaction. The preparation method of lenvatinib according to the present invention produces less difficult-to-remove impurities, facilitates post-processing, facilitates the quality control of raw material drug production, and also provides convenience for subsequent research on preparations.

The invention discloses a lenvatinib synthesizing method.The method includes the steps that 4-amino-3-chlorophenol and benzyl chloroformate are subjected to amidation reaction, the obtained 4-(carbobenzoxy)amino-3-chlorophenol and 4-chlorine-7-methoxyquinoline-6-formamide are subjected to condensation reaction, the obtained 4-[3-chlorine-4-(carbobenzoxy)aminophenoxy]-7-methoxyquinoline-6-formamide and cyclopropylamine are subjected to amidation reaction, and the finished product lenvatinib is obtained.The method is short in process route step, operation is simplified, cost is low, and the method is environmentally friendly and suitable for industrial production.

The invention relates to application of Lenvatinib to preparation of medicine for preventing and curing macular degeneration, and belongs to the field of medicine. The problem that the conventional therapeutic medicine for macular degeneration is low in curative effect and low in patient compliance is solved, and the technical scheme is to provide application of Lenvatinib to preparation of medicine for preventing and curing macular degeneration. Lenvatinib is a multiple target point micromolecularly targeted inhibitor resist to VEGFR, PDGFR and bFGFR, and has been approved by FDA in the market for the treatment of tumors. The invention shows that Lenvatinib has potential for curing macular degeneration, and the application of Lenvatinib is verified by establishing an in vitro and vivo evaluation model, and the application has preferable clinic and social meanings.

The invention relates to a preparation method of lenvatinib, and belongs to the field of medicine chemistry. The preparation method of lenvatinib uses a brand-new preparation scheme; a target compoundmeeting the requirement can be obtained no matter from which intermediates. The method provided by the invention has the advantages that the steps are short; the reaction operation is simple; the safety and the reliability are realized; the yield is high; the cost is low; the purity is high; the pollution is low; the operation is simple, and the like. The total yield of lenvatinib can reach about84 percent; the purity can reach 99.7 percent.

The invention discloses a method for synthesizing lenvatinib. The method comprises the following steps: with 7-methoxy-4-oxo-1,4-dihydro-quinoline-6-formamide as an initial raw material, carrying outan oxo-arylation reaction on the initial raw material and bis(3-chloro-4-amino)phenyl iodine trifluoro-methanesulfonate, carrying out an amidation reaction between 4-(4-amino-3-chloro-phenoxy)-7-methoxy-6-formamide, a product of oxo-arylation reaction, and phenyl chloroformate, and carrying out a urea reaction on a product of amidation reaction and cyromazine, thereby obtaining lenvatinib. The synthetic method has few process route steps and is simple in operation, 7-methoxy-4-oxo-1,4-dihydro-quinoline-6-formamide innovatively replaces 4-chloro-7-methoxyquinoline-6-formamide to serve as the initial raw material, and the method is environmental-friendly and is applicable to industrialized production.

The invention provides application of combination of lenvatinib and a PD-1 monoclonal antibody in preparation of an anti-liver cancer drug, and belongs to the technical field of medicines.The combination of low-dose lenvatinib and the PD-1 monoclonal antibody is adopted, infiltration of T lymphocytes in tumor tissue can be enhanced while normalizing of liver cancer blood vessels is promoted, and then the treatment effect on liver cancer is remarkably enhanced; the compound can be applied to liver cancer prevention and treatment. The invention provides a novel treatment combined medication scheme for the treatment of the liver cancer, and has a good application prospect in the aspect of preventing and treating the liver cancer.

The invention provides a hypoxia-activated prodrug of lenvatinib and application of the hypoxia activated prodrug. A structure of the hypoxia-activated prodrug accords with a general formula (I), wherein the formula (I) is shown in the description, wherein R is -O- and -S-. The drug provided by the invention is stable under normal conditions and has a relatively weak drug function. The hypoxia-activated prodrug is not stable under a hypoxia condition and can generate molecules with the stronger drug function. The drug provided by the invention has good drug function and safety and can be used for preparing drugs for treating tumors.

The invention provides a synthesis method for lenvatinib. The synthesis method takes m-chlorophenol as a raw material and a target product, i.e., the lenvatinib, is obtained through four-step reaction. According to the synthesis method provided by the invention, steps of an original synthesis route are reduced and relatively high yield is kept; and the cost of the raw material is reduced and the atom economy is improved.

The invention discloses a preparation method of lenvatinib and its salts, wherein N-methylpyrrolidone is used as a reaction solvent in the step of condensation with phenyl chloroformate. The preparation method has the advantages that the danger is successfully avoided that N,N-dimethylformamide and phenyl chloroformate react to produce massive gas during large-scale production; the preparation method is stable, the reaction time is short so that better safety is ensured, posttreatment is facilitated, and quality control is facilitated for the production of active pharmaceutical ingredients.

The present invention relates to a compound shown in a general formula (I) and stereoisomers or pharmacologically acceptable salts thereof, as well as to application to preparation of drugs for resisting tumors. The structure of the compound of the general formula (I) is Q-L-R1, and the definition of groups in the general formula (I) is consistent with the definition in the specification.

The invention relates to a preparation method of lenvatinib and salt thereof. The adopted method for preparing the lenvatinib has the advantages that the process is simple, the cost is low, the purity is high, the single-purity content meets the regulations, and the industrial production is easier.

The invention discloses an application of a PERK inhibitor to preparation of a synergist of a liver cancer medicine. By researches, the following case is found that PERK is a target for liver cancer treatment, blockage of PERK activation through a small molecule compound is a new strategy of anti-liver cancer immunotherapy, which uses tumor-related spleen as a target spot, and the PERK has clinical application value. The invention shows that the PERK inhibitor GSK2606414 takes an anti-tumor effect by acting on an immune system in the spleen of a mouse suffering from liver cancer. Moreover, the PERK inhibitor GSK2606414 can significantly and synergistically enhance the liver cancer treatment effect of an anti-PD-1/PD-L1 antibody and Lenvatinib, and can be used as a novel liver cancer treatment drug for treating the liver cancer or enhancing the curative effect.

The invention discloses a hepatocellular carcinoma lenvatinib drug-resistance cell strain. The hepatocellular carcinoma lenvatinib drug-resistance cell strain is characterized in that the cell strainis named human hepatocellular carcinoma lenvatinib drug-resistance cell strain ML30, and the preservation number is (C2019127). A preparation method of the hepatocellular carcinoma lenvatinib drug-resistance cell strain comprises the following steps that 1, after resuscitation of human hepatocellular carcinoma cell strain HuH-7 cells, culturing is carried out in a 5% CO2 incubator at 37 DEG C by aDMEM medium containing fetal bovine serum of 10%; and 2, the human hepatocellular carcinoma cell strain HuH-7 cells in the logarithmic phase are taken, lenvatinib is added in a culture dish, the initial concentration is 3[mu]mol/L, and timely passage or liquid exchange is carried out; after each passage, the concentration of 0.5[mu]mol/L is increased, continuous culture is carried out for more than six months; until the human hepatocellular carcinoma cell strain HuH-7 cells which can grow rapidly in the range of being greater than 30[mu]mol/L are selected and used as the drug-resistance cellstrain, and the drug-resistance cell strain is named as the human hepatocellular carcinoma lenvatinib drug-resistance cell strain ML30. The hepatocellular carcinoma lenvatinib drug-resistance cell strain has important application prospects in studying the mechanism of liver cancer drug-resistance, reversing the drug-resistance of liver cancer cells, guiding the patient to use drugs and establishing a drug-resistance animal model.

The invention provides a lenvatinib synthesis method. The method includes: taking 4-cyano-3-hydroxyaniline as a starting material, subjecting to dimethyl carbonate methylation and oximation through reaction with malonaldehydic acid at the room temperature, performing cyclization under the PPA condition to form 6-cyano-7-methoxy-4-quinolinone, forming 6-cyano-7-methoxy-4-chlorolinone under the action of thionyl chloride, performing cyano hydrolyzing synthesis of 6-formamido-7-methoxy-4-chloroquine which is an intermediate of lenvatinib under an acidic condition, subjecting 4-hydroxy-2-chloroaniline and cyanogen bromide to low-temperature reaction to form 4-hydroxy-2-chlorocyanogen amine, and subjecting 4-hydroxy-2-chlorocyanogen amine and bromopropane to ritter reaction to synthesize 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropyl urea which is another key intermediate of lenvatinib; finally, subjecting the two intermediates including 6-formamido-7-methoxy-4-chloroquine and 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropyl urea to alkylation reaction in an alkaline environment to obtain lenvatinib. By the scheme, mild reaction conditions, avoidance of highly toxic reagents, environmentally friendliness and the like are realized.

The invention belongs to the technical field of medicines and relates to a pharmaceutical composition for treatment of gastric cancer and application of the pharmaceutical composition for treatment of gastric cancer. The pharmaceutical composition for treatment of gastric cancer is provided to overcome technical defects of strong side effects and poor efficacies of existing medicines for treating gastric cancer and is composed of lenvatinib and rhein. The two medicinal active components have a remarkable synergistic effect on inhibition of in-vivo proliferation of human gastric cancer MGC-803.

The invention discloses a lenvatinib and p-hydroxybenzoic acid eutectic crystal and a preparation method thereof. The eutectic crystal comprises lenvatinib and p-hydroxybenzoic acid in a molar ratio of 1: 1, an X-ray powder diffraction pattern of the eutectic crystal measured by Cu K alpha rays has characteristic peaks when diffraction angles 2theta are 6.3+/-0.2 degrees, 10.6+/-0.2 degrees, 12.4+/-0.2 degrees, 14.6+/-0.2 degrees, 17.5+/-0.2 degrees and 18.4+/-0.2 degrees. According to the preparation method, the lenvatinib is converted into a brand-new lenvatinib and p-hydroxybenzoic acid eutectic crystal for the first time, and the lenvatinib and p-hydroxybenzoic acid eutectic crystal has a relatively high dissolution rate and relatively high apparent solubility. The preparation method of the lenvatinib and p-hydroxybenzoic acid eutectic crystal is simple in process, easy to control the crystallization process, good in reproducibility, suitable for industrial production and wide in application prospect.

The invention relates to the field of drug synthesis and discloses a lenvatinib key intermediate 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea, preparation thereof and preparation of lenvatinib. Thelenvatinib intermediate has purity higher than 99% and is prepared by the following steps: (1) cyclopropylamine is subjected to reaction with a compound N,N'-carbonyldiimidazole in a solvent, and N-cyclopropyl-1H-imidazole-1-formamide is obtained; (2) N-cyclopropyl-1H-imidazole-1-formamide and 4-amino-3-chlorophenol are subjected to reaction, and 1-(2-chloro-hydroxyphenyl)-cyclopropylurea is obtained. The intermediate 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea and 4-chloro-7-methoxyquinoline-6-carboxamide are subjected to reaction, and a final product lenvatinib is obtained. The preparation methods are simple to operate, raw materials are cheap and easily available, few difficult-to-remove impurities are produced, water is directly used as a solvent, an organic solvent is not needed, the purity of the product can be higher than 99% with low environmental pollution and simple post-processing, and the methods are green, environmentally friendly, economic and suitable for large-scaleindustrial production.

The invention provides a new Lenvatinib medicine composition and a preparation method thereof. The medicine composition contains Lenvatinib or pharmaceutically acceptable salt of the Lenvatinib and ananti-acid anti-bile gastric mucosa protective agent, wherein the protective agent is hydrotalcite. The medicine composition can fully guarantee that a product is dissolved out, medicine degradation is avoided, and the quality of the product is more favorably guaranteed.

The invention relates to the technical field of tumor drug-resistant genes, in particular to a lenvatinib drug-resistant gene NF1 as well as a screening method and application thereof. The gene sequence of the NF1 is SEQ ID NO: 1. The screening method comprises the following steps: carrying out a pre-experiment to obtain the optimal MOI of the sgRNA library, and determining the concentration of lenvatinib; carrying out an infection Cas9 library experiment to obtain a stable strain; adding lenvatinib into the stable strain for treatment, and analyzing the enrichment condition of the sgRNA through PCR amplification and high-throughput sequencing; screening a drug-resistant gene of lenvatinib; and verifying the function of the effective target gene on liver cancer cell function phenotype and mediated lenvatinib drug resistance. The drug-resistant gene of the lenvatinib is obtained through CRISPR/Cas9 whole-genome library screening, a theoretical basis is provided for reducing the drug resistance of the lenvatinib in the future, a new drug-resistant target is provided for clinical application of the lenvatinib, and guidance is provided for clinical reasonable medication.

The present invention discloses a lenvatinib impurity and a preparation method thereof. The lenvatinib impurity has a structure represented by a formula VI, the impurity uses 2-fluoro-4-hydroxyanilineas a starting material, a lenvatinib impurity intermediate represented by a formula V is prepared through a two-step alkylation reaction, and then the lenvatinib impurity represented by the formula VI is prepared through a condensation reaction. The purity and yield of the prepared impurity are stable, the impurity can be used for quality control of lenvatinib intermediates, bulk drugs and related preparation products, and the quality VI of the bulk drugs and the related preparation products is improved by qualitative and quantitative determination of specific impurities.